Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1202320120050020075
Brain & NeuroRehabilitation
2012 Volume.5 No. 2 p.75 ~ p.81
Efficacy and Safety of Solifenacin Succinate for Urinary Difficulty in Brain Lesion ?Multicenter Prospective Study?
Bok Soo-Kyung

Lim Jun-Ho
Cho Kang-Hee
Choi Eun-Seok
Kim Sang-Soo
Lee Young-Jin
Park Noh-Kyoung
Abstract
Objective: We studied the efficacy and safety of solifenacin for urinary difficulty in brain lesion from multicenter prospective study.

Method: Eighty patients with brain lesion who visited from 5 multicenter department of rehabilitation medicine from May 2009 to June 2010 were included. Patients were treated with solifenacin 5 mg to 10 mg for 12 weeks. The outcome measure was mean change in daily micturation frequency, daily frequency of incontinence, urgency episodes, and nocturia episodes from baseline to week 12. Patient¡¯s attitude to drug was assessed using the BSW Questionnaire (Benefit, Satisfaction and Willingness to Continue Questions).

Results: Sixty-one of 80 were evaluated for effect. All voiding parameters showed significant improvement after 12 weeks of treatment (p£¼0.05). There was no significant difference in efficacy of solifenacin between ischemic and hemorrhagic stroke. A twenty-two patients experienced 27 adverse events (AE). The most frequent AE were dry mouth (12.5%) and constipation (6.3%). Treatment related adverse events with solifenacin were mainly mild in severity, and only led to discontinuation in 6.3% of patients.

Conclusion: Solifenacin succinate improve urinary difficulty symptoms with acceptable efficacy and safety in patient with brain lesion.
KEYWORD
brain injuries, solifenacin succinat, urinary dysfunction
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø